Molgramostim Inhalation Solution

Name: Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: Long-term morbidity
Published: 2026-09-14T15:39:06-04:00

Autoimmune pulmonary alveolar proteinosis

Manufacturer: Savara
Regulatory submission: BLA resubmitted December 2025
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description

Long-term morbidity

2 evidence topics · 3 sources

Progression to pulmonary fibrosis

“a quarter of aPAP patients progressed towards pulmonary fibrosis.” (opens the source at this quote in a new tab)

Infectious complications

“We included 104 patients” (opens the source at this quote in a new tab)
“Thirty-five (34%) patients were hospitalised due to infection.” (opens the source at this quote in a new tab)